<DOC>
	<DOC>NCT00360698</DOC>
	<brief_summary>To evaluate the efficacy of a single injection of glulisine before the main meal added to insulin glargine plus oral antidiabetic drugs (OADs) compared to insulin glargine plus OADs in Type 2 diabetic patients poorly controlled with basal insulin plus OADs.</brief_summary>
	<brief_title>Insulin Glulisine in Type 2 Diabetic Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Insulin glulisine</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Diabetes Mellitus, Type 2 25 &lt; BMI &lt; 45 kg/mÂ² 7,5% &lt; HbA1c &lt; 9% Treated with a basal insulin (NPH, Insulin Zinc, Insulin glargine or Insulin detemir), and at least 1g metformin daily, for more than 3 months Type 1 diabetes mellitus Treatment with OADs only Treatment with thiazolidinediones, with exenatide or with pramlintide Treatment with an insulin other than basal insulin (Premix, rapid insulin, fastacting insulin analogue) Active proliferative diabetic retinopathy, Pregnancy (women of childbearing potential must have a negative pregnancy test at study entry and effective contraception) Breastfeeding History of hypersensitivity to the study drugs or to drugs with a similar chemical structure. Treatment with systemic corticosteroids in the 3 months prior to study entry Treatment with any investigational product in the 2 months prior to study entry Previous treatment with insulin glulisine Likelihood of requiring treatment during the study period with drugs not permitted by the clinical study protocol Clinically relevant cardiovascular, hepatic, neurological, endocrine, or other major disease making implementation of the protocol or interpretation of the study results difficult Impaired hepatic function Impaired renal function History of drug or alcohol abuse The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2011</verification_date>
</DOC>